Actively Recruiting
Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Advanced Pancreatic Cancer
Led by Hangzhou Converd Co., Ltd. · Updated on 2026-02-27
12
Participants Needed
1
Research Sites
196 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The main goal of this clinical trial is to preliminary evaluate the efficacy of recombinant human IL-21-expressing oncolytic vaccinia virus injection (hV01) in patients with advanced pancreatic cancer.And the secondary purpose is to evaluate the safety of hV01.
CONDITIONS
Official Title
Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Advanced Pancreatic Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Signed informed consent form.
- Men or women aged 18 to 75 years.
- Confirmed advanced pancreatic cancer not responding to standard therapy.
- At least one measurable tumor lesion larger than 1.5 cm suitable for injection.
- ECOG performance status of 0 or 1.
- Adequate blood counts and organ function based on specific laboratory tests.
- Female patients of childbearing age must have a negative pregnancy test.
- Agreement to use approved contraceptive methods during treatment and for 3 months after last dose.
You will not qualify if you...
- Recent anti-tumor treatments within specified time frames, including chemotherapy, targeted therapy, immunotherapy, endocrine therapy, Chinese herbal medicine, radiotherapy, or prior oncolytic virus treatment.
- Unresolved toxic effects from previous treatments above grade 1, except safe toxicities like hair loss.
- Uncontrolled central nervous system or meningeal metastases.
- Active autoimmune diseases.
- History of severe cardiovascular or cerebrovascular diseases within the past 12 months.
- Severe arrhythmias or family history of long QT syndrome.
- NYHA classification II or above or left ventricular ejection fraction below 50%.
- Uncontrolled high or low blood pressure.
- Active infections requiring systemic treatment or specific infections like HIV, syphilis, active hepatitis B or C.
- Use of immunomodulatory drugs within 2 weeks before dosing.
- Pregnant or lactating women.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Affiliated Hangzhou First People's Hospital,School of Medicine,Westlake University
Hangzhou, Zhejiang, China
Actively Recruiting
Research Team
M
Meng Li
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here